
3 things to know about Trump's vein condition
CVI is a condition usually caused by damaged leg veins that struggle to send blood back up to the heart. Leavitt said Trump tested for other, more serious complications that sometimes go hand in hand with chronic venous insufficiency, but none were found.
'No signs of heart failure, renal impairment or systemic illness were identified,' she said.
Here's what to know about the condition.
CVI happens when leg veins are damaged and some blood cannot flow from the legs to the heart and pools up in the leg veins, causing swelling and other complications.
The condition is generally mild but can worsen over time. If left untreated, it can cause a host of symptoms, including swelling, cramps, skin changes, leg ulcers, and varicose veins, which are veins that become swollen and twisted.
'What's interesting about this is that it runs the spectrum from very, very mild — where you might have a little bit of swelling, maybe a few varicose veins — to very severe, where you have very severe swelling, skin changes, hyperpigmentation, sort of fibrosis or leather appearance of the skin and even wounds,' said Dr. Thomas Maldonado, a vascular surgeon and medical director of the Venous Thromboembolic Center at NYU Langone Health. 'It's chronic, and over the course of a lifetime, especially as we age, this can be more severe.'
Sean Barbabella, the president's physician, called CVI 'a benign and common condition, particularly in individuals over 70' in a letter released to the public.
The condition can, however, be tied to more serious conditions, including deep vein thrombosis, a blood clot that forms in a deep vein, or pulmonary embolism, a blood clot that stops blood flow to an artery in the lung.
Barbabella said Trump showed no signs of deep vein thrombosis or arterial disease.
CVI affects about 1 in 20 adults, according to the Cleveland Clinic. It's especially common in older adults, and the risk increases with age.
Trump turned 79 last month.
CVI has a handful of treatments, ranging from lifestyle changes to surgery. Barbabella, in his letter, did not specify what treatments — if any — Trump would be undergoing.
Lifestyle changes, like regular exercise, leg elevation and weight management are usually the first steps to treating CVI, according to Maldonado. Compression therapy, which involves tight stockings or bandages, is also an option.
Blood thinners are sometimes used to prevent blood clots from forming.
Some treatments involve injecting a chemical into the veins, which causes scarring, so the veins no longer carry blood.
For worse cases, surgery is sometimes necessary. That can involve tying off the problem vein so that it no longer transports blood, or, if necessary, removing the vein.
Those options are usually only available if the vein is 'superficial,' or close to the skin. In cases where deeper veins are the ones damaged, surgery is usually not an option.
'Sometimes the ultrasound will show it's mostly in the deep system. And unfortunately, those are sacred. We can't really do surgery or shut those veins down. They're critical for the circulation,' said Maldonado.
Maya Kaufman contributed to this report.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
35 minutes ago
- New York Times
Trump Administration Freezes $108 Million in Funds to Duke University
The Trump administration has frozen $108 million in federal funds for Duke University's medical school and health care system, according to two administration officials, after the government accused the university of 'systemic racial discrimination.' Duke University is the latest high-profile school, from Columbia University to Harvard, that the Trump administration has targeted and stripped of a large amount of federal funding, based on vague accusations that the university abets antisemitism or supports diversity, equity and inclusion programs. The move comes amid a wider pressure campaign from the Trump administration to shift the ideological tilt of American higher education. Robert F. Kennedy Jr., the health secretary, and Linda McMahon, the education secretary, sent a letter to Duke administrators on Monday expressing concerns about 'racial preferences in hiring, student admissions, governance, patient care, and other operations' in the university's health care system. In the letter, the officials accused Duke of violating Title VI of the Civil Rights Act, which prohibits discrimination based on race and nationality in programs receiving federal funding. Mr. Kennedy and Ms. McMahon called on Duke Health, the university's health care system, to review all policies 'for the illegal use of race preferences' and to create a 'Merit and Civil Rights Committee' that would work with the federal government. The $108 million cut could be permanent, if the government concludes the university violated the Civil Rights Act, according to the two administration officials, who spoke on condition of anonymity because they were not authorized to speak publicly. Duke University did not immediately respond to an email request for comment. The university is weighing layoffs amid a budget crunch. It's considering about $350 million in cuts, amounting to roughly 10 percent of its budget. In a video message last month, Duke's president, Vincent E. Price, said the university was trying to sort out proposals from the federal government 'that have quite dire implications for the university.' He added there was 'sadly, no scenario in which Duke can or will avoid incurring substantial losses of funding due to these policy changes.' The university has imposed a hiring freeze and developed buyout plans, but Dr. Price said that Duke would 'likely' resort to layoffs.

Washington Post
35 minutes ago
- Washington Post
Vocal FDA critic who became top agency vaccine regulator abruptly departs
Vinay Prasad, a critic of broadly administering coronavirus shots who became the Food and Drug Administration's top vaccine regulator, has left his role months into his job. He's departing after coming under fire from some Republicans and conservative activists, including far-right activist Laura Loomer. The FDA division Prasad led had also been grappling with controversial decisions over how to handle deaths of patients who received a drug made by Sarepta Therapeutics to treat the rare genetic disease Duchenne muscular dystrophy. The Department of Health and Human Services confirmed that Prasad left the job but did not explain why. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' Andrew Nixon, an HHS spokesman, said in a statement. 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA.' Prasad, previously a University of California at San Francisco professor and epidemiologist, did not immediately return a request for comment. Loomer, who had successfully pushed for the ouster of national security officials in the Trump administration, recently turned on Prasad, describing him on her website as 'The Progressive Leftist Saboteur Undermining President Trump's FDA.' She was referring to his previous support for Democratic politicians. Before joining the Trump administration, Prasad gained prominence as a critic of the public health response to the coronavirus pandemic, including annual vaccination for children and vaccine mandates. In May, Prasad replaced Peter Marks, who championed the coronavirus shots, as the head of the FDA's Center for Biologics Evaluation and Research. Health Secretary Robert F. Kennedy Jr. forced Marks out in late March.


New York Times
2 hours ago
- New York Times
Senate Confirms Susan Monarez as C.D.C. Director
Senate Republicans confirmed Susan Monarez, the acting director of the Centers for Disease Control and Prevention and a supporter of Covid vaccines, as the permanent leader of the agency, cementing President Trump's second pick for the job after he withdrew his first nominee just hours before his confirmation hearing earlier this year. Dr. Monarez, an infectious-disease researcher, is the first nonphysician to lead the C.D.C. in more than 50 years. Her confirmation, in a 51-to-47 party-line vote in the Senate, comes as Robert F. Kennedy Jr., the health secretary, has overseen aggressive cuts to the agency — many of which were later reversed — and after he gutted an influential committee that recommends which vaccines Americans should get. Dr. Monarez, 50, assumed the acting director position a few days after Mr. Trump took office in January, leaving her perch as deputy director of a new federal biomedical research agency created during the Biden administration. Dr. Monarez was expected to serve until Mr. Trump's first choice for the job, Dr. Dave Weldon, a former Republican congressman, could be confirmed. But after Mr. Trump decided to withdraw the nomination, Republican aides in the Senate said that Dr. Weldon had failed to impress them with a plan for the agency. Dr. Weldon blamed two Republican senators — Susan Collins of Maine and Bill Cassidy of Louisiana — for turning against him. Some experts said Dr. Monarez was a sharp contrast to Dr. Weldon, whose skeptical views on childhood vaccines aligned with those of Mr. Kennedy and raised alarm in the medical community. Dr. Monarez, in contrast, is a biosecurity expert who endorsed the Covid vaccines, and her selection was seen as signaling a growing impatience with anti-vaccine sentiment. In her time as acting director, subordinates have been interpreting the president's executive orders and various court instructions with little input from Dr. Monarez, according to several C.D.C. employees who spoke on condition of anonymity for fear of retaliation. Her office has also served as a conduit for directives from the White House and the Department of Health and Human Services. For example, she has worked with the cost-cutting initiative known as the Department of Government Efficiency to plan cuts to the agency, according to a former official with knowledge of the matter. And when the Trump administration ordered the C.D.C. to take down pages from its website containing phrases like 'L.G.B.T.Q.' and 'transgender,' Dr. Monarez did not resist or try to preserve important data, according to three people with knowledge of the events, who spoke on condition of anonymity for fear of retaliation.